Akèy › Maladi fwa steatotik
Etid klinik pou Maladi fwa steatotik ap rekrite nan Etazini
65 etid pou Maladi fwa steatotik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- San Antonio, TX17 etid
- New York City, NY16 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Richmond, VA12 etid
- Tucson, AZ10 etid
- Chandler, AZ10 etid
- Orlando, FL9 etid
- Hialeah, FL9 etid
- St. Louis, MO9 etid
- Dallas, TX9 etid
- Durham, NC8 etid
- Dayton, OH8 etid
- Little Rock, AR8 etid
- Los Angeles, CA8 etid
- New Orleans, LA8 etid
- Pasadena, CA8 etid
- Ocala, FL8 etid
- Rochester, MN8 etid
- Akron, OH7 etid
- Seattle, WA7 etid
- Washington, DC7 etid
- Parma, OH7 etid
- Lancaster, CA7 etid
- Brownsville, TX7 etid
- Topeka, KS7 etid
- Las Vegas, NV7 etid
- Round Rock, TX7 etid
- Chicago, IL6 etid
- Sugar Land, TX6 etid
- Cape Coral, FL6 etid
- Sarasota, FL6 etid
- Sandy Springs, GA6 etid
- Peoria, AZ6 etid
- Indianapolis, IN6 etid
- Fort Worth, TX6 etid
- Fayetteville, NC6 etid
- Arlington, TX6 etid
Pa eta
- Alabama4 etid
- Arizona14 etid
- Arkansas8 etid
- Colorado6 etid
- Connecticut5 etid
- Florid20 etid
- Georgia8 etid
- Illinois6 etid
- Indiana9 etid
- Iowa4 etid
- Kalifòni22 etid
- Kansas7 etid
- Kentucky4 etid
- Lwizyàn11 etid
- Maryland8 etid
- Massachusetts9 etid
- Michigan8 etid
- Minnesota9 etid
- Mississippi5 etid
- Missouri14 etid
- Nevada7 etid
- New Jersey6 etid
- New Mexico3 etid
- New York17 etid
- North Carolina13 etid
- Ohio15 etid
- Pennsylvania5 etid
- Rhode Island3 etid
- South Carolina5 etid
- Tennessee7 etid
- Texas20 etid
- Utah5 etid
- Virginia14 etid
- Washington7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT05832229Early Tracking of Childhood Health Determinants (ETCHED) Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 99 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT03481829A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Ap rekriteFaz 2
Laj 5 a 16 · Tout sèks · Mizajou Sep 22, 2026 · NCT06133101A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188Fully Automated High-Throughput Quantitative MRI of the Liver
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 7 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05294471A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374Human Models of Selective Insulin Resistance: Alpelisib, Part I
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 24, 2026 · NCT06354088Quantifying Hepatic Mitochondrial Fluxes in Humans
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT05305287InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT05463796Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
Ap rekriteVolontè an sante akeyi
Laj 25 a 55 · Tout sèks · Mizajou Aug 12, 2026 · NCT06993454Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Aug 10, 2026 · NCT03884075Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 6, 2026 · NCT06335771Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 6, 2026 · NCT06571474Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Ap rekrite
Laj 30 a 70 · Tout sèks · Mizajou Aug 6, 2026 · NCT07646197A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06374875Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
Ap rekriteEtid obsèvasyon
Laj 12 a 18 · Tout sèks · Mizajou Jul 30, 2026 · NCT04634643Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.